SEARCH RESULTS FOR:
Raul Rodriguez
PRESIDENT AND CEO, RIGEL
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and commercializing novel small molecule drugs for immune and hematologic disorders, cancer and rare diseases.
Elizabeth Jeffords
CHIEF COMMERCIAL & STRATEGY OFFICER, ALKAHEST
Alkahest has a unique technology platform for elucidating changes in the plasma proteome in healthy aging and in age-related diseases.
Ricardo Diogo
DIRECTOR BUSINESS DEVELOPMENT, OILTANKING
A look at the liquids storage market in Latin America and its potential consolidation.
Improving Competitiveness for Brazil’s Chemical Industry
Latin America Petrochemicals and Chemicals 2018 APLA Special Edition
A quick look at the sector as Jair Bolsonaro becomes the new president.
Prosperity or Penury – Singapore's Petrochemicals Industry Faces Challenges to Re-invent Itself
Singapore Chemicals 2018
Expert Opinion Article by Steve Jenkins, VP Chemicals Consulting Asia Pacific, PCI Wood Mackenzie.
Michael Quirmbach
CHIEF BUSINESS OFFICER, CORDENPHARMA
CordenPharma is a CDMO supporting pharma and biotech companies, with cGMP facilities across Europe & the US.
Brian Frenzel
CEO, TOSK
Tosk is developing a family of small molecule drugs to prevent the toxic side ef-fects of cancer treatments.
Carlos Ventura
PRESIDENT, BELARUSANGOLA HOLDING LDA
MACIG 2019 Pre-Release
An Angolan company built around partnerships with Belarusian players.
Matthias Vorbeck & Alejandro Gabrielli
GENERAL MANAGER & REGIONAL MANAGER, ANASTACIO OVERSEAS
Latin America Petrochemicals and Chemicals 2018 APLA Special Edition
The company continues expanding in Latin America capitalizing the synergies with the distribution business of Química Anastacio.
Alan Seem
PARTNER, JONES DAY
Jones Day is the largest law firm in the United States and one of the ten largest firms globally.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latam North and Caribbean Mining 2025 - Digital Interactive
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
